Leerink Partnrs Has Bullish Forecast for ACAD Q4 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Analysts at Leerink Partnrs boosted their Q4 2024 earnings estimates for ACADIA Pharmaceuticals in a research note issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings of $0.12 per share for the quarter, up from their previous forecast of $0.10. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. Leerink Partnrs also issued estimates for ACADIA Pharmaceuticals’ FY2025 earnings at $0.75 EPS, FY2027 earnings at $1.44 EPS and FY2028 earnings at $2.13 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.06. The company had revenue of $250.40 million during the quarter, compared to analyst estimates of $248.83 million. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The firm’s quarterly revenue was up 18.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.40) earnings per share.

ACAD has been the topic of several other research reports. Guggenheim lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the company from $23.00 to $20.00 in a report on Friday, January 3rd. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Raymond James restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 10th. Finally, StockNews.com downgraded ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 14th. Seven equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $25.25.

ACADIA Pharmaceuticals Price Performance

Shares of NASDAQ ACAD opened at $18.66 on Thursday. The stock has a market capitalization of $3.10 billion, a P/E ratio of 23.92 and a beta of 0.37. ACADIA Pharmaceuticals has a one year low of $14.15 and a one year high of $26.83. The firm’s 50 day simple moving average is $17.50 and its two-hundred day simple moving average is $16.64.

Insider Activity at ACADIA Pharmaceuticals

In related news, insider James Kihara sold 4,073 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total value of $68,467.13. Following the transaction, the insider now directly owns 19,863 shares of the company’s stock, valued at approximately $333,897.03. This represents a 17.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Brendan Teehan sold 10,329 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total value of $173,630.49. Following the sale, the chief operating officer now directly owns 62,105 shares in the company, valued at $1,043,985.05. This trade represents a 14.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 24,661 shares of company stock valued at $414,551 in the last 90 days. Corporate insiders own 28.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ACAD. Park Place Capital Corp bought a new stake in ACADIA Pharmaceuticals during the third quarter valued at about $25,000. Values First Advisors Inc. purchased a new position in shares of ACADIA Pharmaceuticals in the third quarter worth $27,000. R Squared Ltd bought a new position in shares of ACADIA Pharmaceuticals during the fourth quarter worth $47,000. Quest Partners LLC grew its stake in ACADIA Pharmaceuticals by 42.3% during the third quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 1,047 shares in the last quarter. Finally, KBC Group NV increased its holdings in ACADIA Pharmaceuticals by 67.0% in the 4th quarter. KBC Group NV now owns 5,093 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 2,044 shares during the last quarter. Institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.